+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Vitamin D Therapy Market Report 2021-2031

18 February 2021
Pharma

Visiongain has published a new report on Vitamin D Therapy Market Report 2021-2031: Forecasts by Analog (Vitamin D2, Vitamin D3), Form (Dry, Liquid), Application (Functional Food & Beverage, Pharma, Feed, and Personal Care), End User (Children, Adult, and Pregnant Women), IU Strength. PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Vitamin D therapy market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.

Vitamin D is considered to be a group of fat soluble vitamin that helps in increasing the intestinal absorption of calcium, phosphate and magnesium. The major vitamin D compounds in humans include D3 and vitamin D2. Vitamin D deficiency is one of the common problems among the people due to less exposure to symptoms of Vitamin D deficiency is muscle weakness and bone pain.

Vitamin D helps calcium absorption in the stomach and retains adequate serum calcium and phosphate absorptions to aid normal bone mineralization and to prevent hypocalcemic tetany (involuntary contraction of muscles, leading to cramps and spasms). It is also needed for bone growth and bone remodelling by osteoblasts and osteoclasts [1-3]. Without sufficient vitamin D, bones can become thin, brittle, or deformed.

COVID-19 Impact on Vitamin D therapy Market
The market is growing in this pandemic of COVID19 due to awareness of the healthcare segment among the masses. In this time period many programme are held by certain organisation regarding self-care oh health. People are getting aware of certain health care. Hence this market is expected to grow in future periods.

Market Drivers
The global Vitamin D Therapy market is driven by the factors such as increase in the target patient population, rise in awareness about vitamin D deficiency, surge in levels of malnutrition, increase in patient compliance to oral medication, rise in prevalence of deficiency of Vitamin D, aging population, sedentary lifestyles and lack of exposure to sun.

Market Opportunities
The opportunities of growth for the Vitamin D market are yet to be explored and the countries with high prevalence of undernutrition people can prove to be a growth prospect for the company’s manufacturing Vitamin D drugs and dosages.

Market Challenge
The fortification of foods, which are already rich in Vitamin D, are likely to pose a challenge to the growth of Vitamin D therapy Market.

Competitive Landscape
Global Vitamin D Therapy Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. Major players profiled in the report, include: Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd (India).

Recent Developments:
• In 2018, GlaxoSmithKline PLC completed the acquisition of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for USD 13 billion.
• In 2018, GlaxoSmithKline plc and Pfizer Inc. join forces to form a new world-leading consumer healthcare joint venture. The joint venture has played a vital role in the categories of pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health, and therapeutic oral health.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read